支气管动脉灌注+外周静脉持续化疗双径路治疗晚期肺癌的临床研究  

Clinical Study on Bronchial Arterial Infusing Pluse Peripheral Vein Continuous Chemotherapy in Treating Advanced Lung Cancer

作　　者：毋永娟[1] 丁晓岭[2] 王晓红[1] 鲍力[1] 钱海龙[1] 张强[1] 石宝琪[1] 郭俊[1] 

机构地区：[1]包头市第七医院肿瘤内科,内蒙古包头014030 [2]内蒙古科技大学包头医学院图书馆,内蒙古包头014010

出　　处：《内蒙古医学杂志》2005年第10期881-883,共3页Inner Mongolia Medical Journal

摘　　要：目的:探讨支气管动脉灌注细胞周期非特异性药物联合外周静脉持续化疗,静点细胞周期特异性药物治疗Ⅲ期以上肺癌临床疗效和毒副反应.方法:对84例Ⅲ期以上肺癌随机分为治疗组42例,对照组42例.治疗组以支气管动脉灌注+外周静脉持续化疗:a.小细胞肺癌支气管动脉灌注DDP 80～120mg或CBP 300～400mg/次或CTX 0.8～1.0/次,12h后外周静点V-P16:100mg/m2/d1～5或V-m26:100mg/m2/d1～3或HCPT 10mg/d1～5;b.非小细胞肺癌支气管动脉灌注E-ADM 80mg/m2、MMC 4mg/m2、DDP100mg/m2,12h后外周静脉持续点滴5-Fu 0.5/m2/d1～5或NVB 40mg/nm2/d1,8或VDS 3mg/m2/d1～8.对照组42例小细胞肺癌以CE方案为主,非小细胞肺癌以MVP或NP方案为主,全组治疗均在3个周期以上,可评价疗效.结果:近期客观疗效:治疗组42例,CR+PR 32例,总有效率76.1%;对照组CR+PR 17例,总有效率40.4%.两组近期疗效比较有非常显著差异(P＜0.01);治疗组中位缓解期6.5个月,对照组中位缓解期4.2个月,两组比较有显著差异(P＜0.05).远期疗效:治疗组中位生存14.6个月,对照组中位生存11.5个月,有显著性差异(P＜0.05),化疗毒副反应两组无差异.结论:按照细胞周期动力学作用,将细胞周期非特异性药物进行BAI联合细胞周期特异性药物外周静脉化疗,治疗中晚期肺癌,可以提高疗效及中位生存期,未增长毒副反应,利于临床推广使用.Objective： To investigate the clinical effect and toxic and side effect of bronchial arterial infusing plus peripheral vein continuous chemotherapy on lung cancer in stage Ⅲ and above. Methods：84 cases with lung cancer in stage Ⅲ and above were randomly divided into two groups： treatment group （ n = 42） and control group （ n = 42）. 42 cases in treatment group were treated with bronchial arterial infusing plus peripheral vein continuous chemotherapy, a. Cases with small cell lung cancer were administrated with bronchial arterial infusing DDP 80 - 120mg daily or CBP 300-400mg daily or CTX 0.8 - 1.0 daily, and intravenous V - P16 ： 100mg/m^2/ d1-5 or V - m26 ： 100g/m^2/d1-3 or HCPT 10mg/d1-5 after 12 hours, b. Cases with non - small cell lung cancer were administrated with bronchial arterial infusing E - ADM 80mg/m^2 or MMC 4mg/m^2 or DDP 100mg/m^2 , and intravenous 5 - Fu 0.5/m^2/d1-5 or NVB 40mg/m^2/d1-8 or VDS 3mg/m^2/d1-8 after 12 hours. In control group, cases with small cell lung cancer were treated with CE regimen, those with non - small cell lung cancer with MVP or NP ones for three treatment cycles or above, then the effect was evaluated. Results： The total effective rate of short - term efficacy was 76. 1% in treatment group and 40.4 % in control group, the difference was markedly significant （ P 〈 0.01 ）. The median paracmasis was 6.5 months in treatment group and 4.2 months in control group, the median survival time was 14.6 months in treatment group and 11.5 months in control group, showing significant difference （P 〈 0.05）. There was ,lo difference in toxic and side effect of chemotherapy between two groups. Conclusion：The bronchial arterial infusing plus peripheral vein continuous chemotherapy for advanced lung cancer should be recommended, for improving curative effect and median survival time without iracreasing toxic and side effect.

关 键 词：肺癌 支气管动脉灌注 双径路化疗 

分 类 号：R734.2[医药卫生—肿瘤] R453.9[医药卫生—临床医学]